ID   SERB_HUMAN              Reviewed;         225 AA.
AC   P78330; B2RCR5; Q7Z3S5;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   26-APR-2005, sequence version 2.
DT   12-APR-2017, entry version 162.
DE   RecName: Full=Phosphoserine phosphatase;
DE            Short=PSP;
DE            Short=PSPase;
DE            EC=3.1.3.3;
DE   AltName: Full=L-3-phosphoserine phosphatase;
DE   AltName: Full=O-phosphoserine phosphohydrolase;
GN   Name=PSPH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9188776; DOI=10.1016/S0014-5793(97)00438-9;
RA   Collet J.-F., Gerin I., Rider M.H., Veiga-Da-Cunha M.,
RA   Van Schaftingen E.;
RT   "Human L-3-phosphoserine phosphatase: sequence, expression and
RT   evidence for a phosphoenzyme intermediate.";
RL   FEBS Lett. 408:281-284(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrial tumor;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 3-225 IN COMPLEXES WITH
RP   INHIBITOR 2-AMINO-3-PHOSPHONOPROPIONIC ACID; SERINE AND PHOSPHATE ION,
RP   SUBUNIT, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF SER-23;
RP   GLU-29; ARG-65; ASN-133; THR-182 AND ARG-202.
RX   PubMed=12213811; DOI=10.1074/jbc.M204866200;
RA   Kim H.Y., Heo Y.S., Kim J.H., Park M.H., Moon J., Kim E., Kwon D.,
RA   Yoon J., Shin D., Jeong E.J., Park S.Y., Lee T.G., Jeon Y.H., Ro S.,
RA   Cho J.M., Hwang K.Y.;
RT   "Molecular basis for the local conformational rearrangement of human
RT   phosphoserine phosphatase.";
RL   J. Biol. Chem. 277:46651-46658(2002).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.53 ANGSTROMS) OF 3-225 IN COMPLEX WITH
RP   CALCIUM IONS, FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND SUBUNIT.
RX   PubMed=12777757; DOI=10.1107/S0907444903005407;
RA   Peeraer Y., Rabijns A., Verboven C., Collet J.F., Van Schaftingen E.,
RA   De Ranter C.;
RT   "High-resolution structure of human phosphoserine phosphatase in open
RT   conformation.";
RL   Acta Crystallogr. D 59:971-977(2003).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.53 ANGSTROMS) OF 3-225 IN COMPLEX WITH
RP   CALCIUM IONS, COFACTOR, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=15291819; DOI=10.1111/j.0014-2956.2004.04277.x;
RA   Peeraer Y., Rabijns A., Collet J.F., Van Schaftingen E., De Ranter C.;
RT   "How calcium inhibits the magnesium-dependent enzyme human
RT   phosphoserine phosphatase.";
RL   Eur. J. Biochem. 271:3421-3427(2004).
RN   [11]
RP   VARIANTS PSPHD ASN-32 AND THR-52.
RX   PubMed=14673469; DOI=10.1038/sj.ejhg.5201083;
RA   Veiga-da-Cunha M., Collet J.F., Prieur B., Jaeken J., Peeraer Y.,
RA   Rabbijns A., Van Schaftingen E.;
RT   "Mutations responsible for 3-phosphoserine phosphatase deficiency.";
RL   Eur. J. Hum. Genet. 12:163-166(2004).
CC   -!- FUNCTION: Catalyzes the last step in the biosynthesis of serine
CC       from carbohydrates. The reaction mechanism proceeds via the
CC       formation of a phosphoryl-enzyme intermediates.
CC       {ECO:0000269|PubMed:12777757}.
CC   -!- CATALYTIC ACTIVITY: O-phospho-L(or D)-serine + H(2)O = L(or D)-
CC       serine + phosphate. {ECO:0000269|PubMed:12213811,
CC       ECO:0000269|PubMed:12777757, ECO:0000269|PubMed:15291819}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15291819};
CC       Note=Binds 1 Mg(2+) ion per subunit.
CC       {ECO:0000269|PubMed:15291819};
CC   -!- ENZYME REGULATION: Inhibited by calcium ions.
CC       {ECO:0000269|PubMed:15291819}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine
CC       from 3-phospho-D-glycerate: step 3/3.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12213811,
CC       ECO:0000269|PubMed:12777757, ECO:0000269|PubMed:15291819}.
CC   -!- DISEASE: Phosphoserine phosphatase deficiency (PSPHD)
CC       [MIM:614023]: A disorder that results in pre- and postnatal growth
CC       retardation, moderate psychomotor retardation and facial features
CC       suggestive of Williams syndrome. {ECO:0000269|PubMed:14673469}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the HAD-like hydrolase superfamily. SerB
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10275; CAA71318.1; -; mRNA.
DR   EMBL; AK315235; BAG37662.1; -; mRNA.
DR   EMBL; BX537439; CAD97681.1; -; mRNA.
DR   EMBL; CH471140; EAX07968.1; -; Genomic_DNA.
DR   EMBL; BC063614; AAH63614.1; -; mRNA.
DR   CCDS; CCDS5522.1; -.
DR   RefSeq; NP_004568.2; NM_004577.3.
DR   RefSeq; XP_005271830.1; XM_005271773.1.
DR   RefSeq; XP_005271831.1; XM_005271774.1.
DR   RefSeq; XP_005271832.1; XM_005271775.1.
DR   RefSeq; XP_005271833.1; XM_005271776.1.
DR   RefSeq; XP_006715823.1; XM_006715760.1.
DR   RefSeq; XP_011513763.1; XM_011515461.1.
DR   RefSeq; XP_016867955.1; XM_017012466.1.
DR   RefSeq; XP_016867956.1; XM_017012467.1.
DR   UniGene; Hs.512656; -.
DR   PDB; 1L8L; X-ray; 2.51 A; A/B=1-225.
DR   PDB; 1L8O; X-ray; 2.80 A; A/B=1-225.
DR   PDB; 1NNL; X-ray; 1.53 A; A/B=1-225.
DR   PDBsum; 1L8L; -.
DR   PDBsum; 1L8O; -.
DR   PDBsum; 1NNL; -.
DR   ProteinModelPortal; P78330; -.
DR   SMR; P78330; -.
DR   BioGrid; 111695; 10.
DR   IntAct; P78330; 1.
DR   STRING; 9606.ENSP00000275605; -.
DR   DrugBank; DB03292; D-2-Amino-3-Phosphono-Propionic Acid.
DR   DEPOD; P78330; -.
DR   iPTMnet; P78330; -.
DR   PhosphoSitePlus; P78330; -.
DR   BioMuta; PSPH; -.
DR   DMDM; 62906870; -.
DR   EPD; P78330; -.
DR   MaxQB; P78330; -.
DR   PaxDb; P78330; -.
DR   PeptideAtlas; P78330; -.
DR   PRIDE; P78330; -.
DR   DNASU; 5723; -.
DR   Ensembl; ENST00000275605; ENSP00000275605; ENSG00000146733.
DR   Ensembl; ENST00000395471; ENSP00000378854; ENSG00000146733.
DR   Ensembl; ENST00000437355; ENSP00000401639; ENSG00000146733.
DR   GeneID; 5723; -.
DR   KEGG; hsa:5723; -.
DR   UCSC; uc003trh.4; human.
DR   CTD; 5723; -.
DR   DisGeNET; 5723; -.
DR   GeneCards; PSPH; -.
DR   HGNC; HGNC:9577; PSPH.
DR   HPA; HPA020376; -.
DR   HPA; HPA029515; -.
DR   MalaCards; PSPH; -.
DR   MIM; 172480; gene.
DR   MIM; 614023; phenotype.
DR   neXtProt; NX_P78330; -.
DR   OpenTargets; ENSG00000146733; -.
DR   Orphanet; 79350; 3-phosphoserine phosphatase deficiency.
DR   PharmGKB; PA33928; -.
DR   eggNOG; KOG1615; Eukaryota.
DR   eggNOG; COG0560; LUCA.
DR   GeneTree; ENSGT00390000003115; -.
DR   HOGENOM; HOG000231116; -.
DR   HOVERGEN; HBG057486; -.
DR   InParanoid; P78330; -.
DR   KO; K01079; -.
DR   OMA; RAQYYVT; -.
DR   OrthoDB; EOG091G0JBZ; -.
DR   PhylomeDB; P78330; -.
DR   TreeFam; TF315024; -.
DR   BioCyc; MetaCyc:HS07370-MONOMER; -.
DR   Reactome; R-HSA-977347; Serine biosynthesis.
DR   UniPathway; UPA00135; UER00198.
DR   ChiTaRS; PSPH; human.
DR   EvolutionaryTrace; P78330; -.
DR   GeneWiki; PSPH; -.
DR   GenomeRNAi; 5723; -.
DR   PRO; PR:P78330; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000146733; -.
DR   CleanEx; HS_PSPH; -.
DR   ExpressionAtlas; P78330; baseline and differential.
DR   Genevisible; P78330; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004647; F:phosphoserine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0006564; P:L-serine biosynthetic process; TAS:Reactome.
DR   GO; GO:0006563; P:L-serine metabolic process; IDA:UniProtKB.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   Gene3D; 1.10.150.210; -; 1.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR023190; Pser_Pase_dom_2.
DR   SUPFAM; SSF56784; SSF56784; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Amino-acid biosynthesis; Complete proteome;
KW   Disease mutation; Hydrolase; Magnesium; Metal-binding;
KW   Reference proteome; Serine biosynthesis.
FT   CHAIN         1    225       Phosphoserine phosphatase.
FT                                /FTId=PRO_0000156879.
FT   REGION      109    110       Substrate binding.
FT   ACT_SITE     20     20       Nucleophile.
FT   ACT_SITE     22     22       Proton donor.
FT   METAL        20     20       Magnesium.
FT   METAL        22     22       Magnesium; via carbonyl oxygen.
FT   METAL       179    179       Magnesium.
FT   BINDING      29     29       Substrate.
FT   BINDING      65     65       Substrate.
FT   BINDING     158    158       Substrate.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   VARIANT      32     32       D -> N (in PSPHD; dbSNP:rs28933976).
FT                                {ECO:0000269|PubMed:14673469}.
FT                                /FTId=VAR_022378.
FT   VARIANT      52     52       M -> T (in PSPHD; dbSNP:rs104894036).
FT                                {ECO:0000269|PubMed:14673469}.
FT                                /FTId=VAR_022379.
FT   MUTAGEN      23     23       S->A: Reduces activity by about 50%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN      23     23       S->T: Reduces activity by about 80%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN      29     29       E->D: Reduces activity by about 95%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN      29     29       E->Q: Loss of activity.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN      65     65       R->A,K: Loss of activity.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN     133    133       N->A: Reduces activity by about 75%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN     182    182       T->S: Reduces activity by about 99%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN     182    182       T->V: Reduces activity by about 25%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN     202    202       R->A: Reduces activity by about 99%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   MUTAGEN     202    202       R->K: Reduces activity by about 95%.
FT                                {ECO:0000269|PubMed:12213811}.
FT   CONFLICT      2      2       V -> I (in Ref. 1; CAA71318).
FT                                {ECO:0000305}.
FT   HELIX         6     13       {ECO:0000244|PDB:1NNL}.
FT   STRAND       15     20       {ECO:0000244|PDB:1NNL}.
FT   TURN         23     25       {ECO:0000244|PDB:1NNL}.
FT   STRAND       26     28       {ECO:0000244|PDB:1NNL}.
FT   HELIX        30     37       {ECO:0000244|PDB:1NNL}.
FT   TURN         41     43       {ECO:0000244|PDB:1NNL}.
FT   TURN         45     47       {ECO:0000244|PDB:1L8L}.
FT   TURN         49     52       {ECO:0000244|PDB:1L8L}.
FT   HELIX        58     69       {ECO:0000244|PDB:1NNL}.
FT   HELIX        73     82       {ECO:0000244|PDB:1NNL}.
FT   HELIX        91    100       {ECO:0000244|PDB:1NNL}.
FT   STRAND      104    112       {ECO:0000244|PDB:1NNL}.
FT   HELIX       113    122       {ECO:0000244|PDB:1NNL}.
FT   HELIX       127    129       {ECO:0000244|PDB:1NNL}.
FT   STRAND      130    133       {ECO:0000244|PDB:1NNL}.
FT   STRAND      135    137       {ECO:0000244|PDB:1NNL}.
FT   STRAND      143    146       {ECO:0000244|PDB:1NNL}.
FT   STRAND      148    150       {ECO:0000244|PDB:1L8L}.
FT   HELIX       151    153       {ECO:0000244|PDB:1NNL}.
FT   HELIX       157    169       {ECO:0000244|PDB:1NNL}.
FT   STRAND      174    180       {ECO:0000244|PDB:1NNL}.
FT   HELIX       181    184       {ECO:0000244|PDB:1NNL}.
FT   TURN        185    189       {ECO:0000244|PDB:1NNL}.
FT   STRAND      190    196       {ECO:0000244|PDB:1NNL}.
FT   HELIX       203    208       {ECO:0000244|PDB:1NNL}.
FT   STRAND      210    214       {ECO:0000244|PDB:1NNL}.
FT   HELIX       216    219       {ECO:0000244|PDB:1NNL}.
FT   HELIX       221    224       {ECO:0000244|PDB:1L8L}.
SQ   SEQUENCE   225 AA;  25008 MW;  BD5D72697747FA30 CRC64;
     MVSHSELRKL FYSADAVCFD VDSTVIREEG IDELAKICGV EDAVSEMTRR AMGGAVPFKA
     ALTERLALIQ PSREQVQRLI AEQPPHLTPG IRELVSRLQE RNVQVFLISG GFRSIVEHVA
     SKLNIPATNV FANRLKFYFN GEYAGFDETQ PTAESGGKGK VIKLLKEKFH FKKIIMIGDG
     ATDMEACPPA DAFIGFGGNV IRQQVKDNAK WYITDFVELL GELEE
//
